Latest News- Irritable Bowel Syndrome Market: IBS-D is expected to lead the Type segment during 2024-2028

The Irritable Bowel Syndrome Market is being driven by Increasing prevalence of IBS

The Irritable Bowel Syndrome Market is expected to grow at a CAGR of 9.3% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 1931.9 million. The global Irritable Bowel Syndrome (IBS) market is witnessing a significant trend with an increasing number of regulatory approvals for innovative therapies aimed at managing IBS symptoms. Notable agencies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have expedited the approval process for these treatments due to the substantial impact IBS has on patients' quality of life. In a recent development, Ironwood Pharmaceuticals announced the FDA's approval of a new indication for Linzess (linaclotide) to treat functional constipation in pediatric patients aged 6 to 17 years. This approval underscores the growing recognition of the urgent need for effective treatment options in the IBS market. 

Get more information on Irritable Bowel Syndrome Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Type
  • IBS-D
  • IBS-C
  • IBS-M
• Drug Class
  • Antibiotics
  • Guanylate cyclase-C agonists
  • Mu-opioid receptor agonists
  • Chloride channel activators
  • Antispasmodics
  • Antidiarrheals
  • Others
• Distribution Channel
  • Offline
  • Online
• Treatment Type
  • Medications
  • Dietary Supplements
  • Therapeutics
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
    • France
  • Asia
    • China
    • India
    • Japan
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Increasing prevalence of IBS
• Growing awareness and diagnosis of IBS
• Rising global healthcare expenditure

However, the market also witnesses some limitations, which are as follows:

• Side effects associated with existing medications
• Increasing number of product recalls
• Prevalence of counterfeit drugs

Benefits of Buying Global Irritable Bowel Syndrome Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Irritable Bowel Syndrome Market Research Report

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Irritable Bowel Syndrome (IBS) market encompasses various treatments and resources. These include colorectal surgery, mental health interventions, and supplements like probiotics, prebiotics, and fiber. Medications such as antidiarrheal, antispasmodic, anti-anxiety, and pain relievers are also utilized. Digital tools like IBS-specific apps, online resources, community forums, and telemedicine are essential. Patient advocacy, research funding, data collection, bioinformatics, machine learning, artificial intelligence, and precision medicine are pivotal in advancing IBS understanding and treatment. Prevention strategies complete the comprehensive approach to managing IBS.

Market Research Overview

The Irritable Bowel Syndrome (IBS) market encompasses businesses involved in the research and development (R&D) or production of IBS medications, therapies, and diagnostic tools. According to Technavio, the global pharmaceuticals market, which includes the revenue generated by manufacturers and providers of pharmaceuticals, is projected to expand due to several factors. One significant driver is the increasing aging population, with Europe and the US projected to have over 25% of their populations aged 60 and above by 2030 and 2050, respectively. This demographic shift will lead to a higher demand for IBS treatments and medications to manage symptoms and improve the quality of life for those affected.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/